Visioneering Technologies, Inc. (Company) is expected to be admitted to the official list of ASX Limited (ASX) today, 27 March 2017.
Official quotation of the Company’s securities is expected to commence at 11.00 am AEDT on Tuesday, 28 March 2017.
The Company raised A$33.3 million pursuant to the offer under the replacement prospectus dated 24 February 2017 (Prospectus) by the issue of 79,365,079 CHESS Depositary Interests at an issue price of $0.42 per CDI.
Quoted securities: |
173,012,109 Class A common stock (to be settled on ASX in the form of CDIs) |
CDI ratio to underlying shares: |
1 CDI is equivalent to one share |
ASX Code: |
VTI |
Time: |
11:00 am AEDT |
Date: |
Tuesday, 28 March 2017 |
ASX Trade Abbreviation: |
VISIONTECH |
ISIN: |
AU000000VTI2 |
Home Branch: |
Sydney |
Industry Classification: |
3510 – Health Care Equipment and Services |
Registered Office: |
4555 Mansell Road, Suite 300 Alpharetta, Georgia 30022, United States +1 844 884 5367 |
Company Secretary: |
Leanne Ralph |
Share Registry: |
Advanced Share Registry Limited GPO Box 2975, 1300 850 505 or +61 3 9415 4000 |
Balance Date: |
31 December |
CHESS: |
Participating. The Company will also operate an issuer sponsored sub-register. |
Place of Incorporation: |
Delaware, United States |
Dividend Policy: |
The Company currently does not intend to pay dividends |
Activities:
|
Design, sale and distribution of NaturalVueTM contact lenses |
Restricted Securities: |
7,835,660 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 24 months from the date of commencement of official quotation. 6,981,550 options exercisable at various prices and expiring on various dates classified by ASX as restricted securities and to be held in escrow for a period of 24 months from the date of commencement of official quotation. 317,460 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 18 July 2016. 277,778 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 20 July 2016. 3,095,239 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 21 July 2016. 555,555 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 22 July 2016. 2,329,379 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 26 July 2016. 2,103,175 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 27 July 2016. 128,571 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 4 August 2016. 39,683 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 8 August 2016. 79,365 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 9 August 2016. 39,683 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 1 November 2016. 39,683 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 2 November 2016. 1,587,302 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 7 November 2016. 5,548,714 Class A common stock or CDIs classified by ASX as restricted securities and to be held in escrow for a period of 12 months from 22 March 2017.
|
Securities not quoted: |
In addition to the restricted options above; 4,561,524 unquoted options exercisable at various prices and expiring on various dates issued under the Company’s 2008 Equity Incentive Plan.
|
Please refer to the Prospectus.
For further information, please refer to the Prospectus
Belinda Chiu